(2S)-2-(3,4-dichlorophenyl)pent-4-en-1-ol | 167485-86-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-(3,4-dichlorophenyl)pent-4-en-1-ol
• 英文别名: (S)-2-(3,4-dichlorophenyl)-4-pentenol；4(S)-(3,4-dichlorophenyl)-5-hydroxypent-1-ene；2-(S)-(3,4-dichlorophenyl)-4-penten-1-ol
• CAS: 167485-86-1
• 化学式: C₁₁H₁₂Cl₂O
• 分子量: 231.122
• InChiKey: WXVZYZNZRCAPET-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2S)-2-(3,4-dichlorophenyl)pent-4-en-1-ol 在 sodium periodate 、 四氧化锇 、 N-甲基吲哚酮 、 水 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 、 叔丁醇 为溶剂， 生成 Benzoic acid (S)-2-(3,4-dichloro-phenyl)-4-oxo-butyl ester
  参考文献：
  名称：

  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure–activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes

  摘要：

  Screening of the Merck sample collection for compounds with CCR5 receptor binding afforded (2S)-2-(3,4-dichlorophenyl)- 1-[N-(methyl)-N-(phenylsulfonyl)amino]-4,4'-piperidin-1'-yl)]butane S-oxide (4) as a potent lead structure having an IC50 binding affinity of 35 nM. Herein, we describe the discovery of this lead structure and our initial structure-activity relationship studies directed toward the requirement for and optimization of the 1-amino fragment. (C) 2001 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(00)00637-5
• 作为产物：
  描述：

  (S)-2-(3',4'-dichlorophenyl)pent-4-enoic acid 在 sodium hydroxide 作用下， 生成 (2S)-2-(3,4-dichlorophenyl)pent-4-en-1-ol
  参考文献：
  名称：

  Spiro-substituted azacycles as neurokinin antagonists

  摘要：

  披露的是公式I的螺环取代的氮杂环，它们是速激肽受体拮抗剂，可用于治疗炎症性疾病、疼痛或偏头痛以及哮喘。特别是，公式I的化合物显示出是神经激肽拮抗剂。

  公开号：

  US06013652A1

文献信息

• Spiro-substituted azacycles as neurokinin antagonists
  申请人：Merck & Co., Inc.

  公开号：US06013652A1

  公开（公告）日：2000-01-11

  Disclosed are spiro-substituted azacycles of formula I are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma. In particular compounds of formula I are shown to be neurokinin antagonists.

  披露的是公式I的螺环取代的氮杂环，它们是速激肽受体拮抗剂，可用于治疗炎症性疾病、疼痛或偏头痛以及哮喘。特别是，公式I的化合物显示出是神经激肽拮抗剂。
• Spiro-substituted azacycles as modulators of chemokine receptor activity
  申请人：Merck & Co., Inc.

  公开号：US05962462A1

  公开（公告）日：1999-10-05

  The present invention is directed to spiro-substituted azacycles of the Formula 1: ##STR1## (wherein R.sub.1, l, m, Q, W, X, Y, and Z are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.

  本发明涉及式1所示的螺环取代的氮杂环化合物：##STR1##（其中R.sub.1，l，m，Q，W，X，Y和Z在此定义），这些化合物可用作调节化学趋化因子受体活性的调节剂。特别是，这些化合物作为化学趋化因子受体CCR-1、CCR-2、CCR-2A、CCR-2B、CCR-3、CCR-4、CCR-5、CXCR-3和/或CXCR-4的调节剂是有用的。
• Piperidine derivatives useful as neurokinin antagonists
  申请人：Zeneca Limited

  公开号：US05635509A1

  公开（公告）日：1997-06-03

  Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  式I的化合物##STR1##其中Q.sup.1、Q.sup.2、Q.sup.3和Q.sup.4具有规范中给定的任何含义，它们的N-氧化物以及它们的药用盐是神经激肽A的非肽类拮抗剂，用于治疗哮喘等。还公开了制药组合物、制备式I化合物和中间体的方法。
• Quaternary ammonium compounds as tachykinin antagonists
  申请人：Pfizer INC

  公开号：US06207678B1

  公开（公告）日：2001-03-27

  The present invention provides a compound of formula (I) wherein R is phenyl, C3-C7 cycloalkyl or heteroaryl, each of which being optionally benzo- or C3-C7 cycloalkyl-fused and optionally substituted, including in the benzo- or C3-C7 cycloalkyl-fused portion, by from 1 to 3 substituents each independently selected from C1-C4 alkyl, fluoro(C1-C4)alkyl, C1-C4 alkoxy, fluoro(C1-C4)alkoxy, phenoxy, C2-C4 alkanoyl, halo, C1-C4 alkoxycarbonyl, C3-C7 cycloalkyl, —S(O)m(C1-C4 alkyl), cyano, —NR2R3, —S(O)mNR2R3, —NR4(C1-C4 alkanoyl) and —CONR2R3, or R is 2,3-dihydrobenzo[b]furanyl or chromanyl; R1 is H or C1-C6 alkyl; W is a direct link, methylene or ethylene; X is unbranched C2-C4 alkylene; Y is phenyl, naphthyl, benzyl, pyridyl, thienyl or C3-C7 cycloalkyl, each of which being optionally substituted by from 1 to 3 substituents each independently selected from C1-C4 alkyl, fluoro(C1-C4)alkyl, C1-C4 alkoxy, fluoro(C1-C4)alkoxy, halo and cyano; Ar is phenyl, naphthyl, benzyl, thienyl, benzo[b]thienyl or indolyl, each of which being optionally substituted by from 1 to 3 substituents each independently selected from C1-C4 alkyl, fluoro(C1-C4)alkyl, C1-C4 alkoxy, fluoro(C1-C4)alkoxy, halo and cyano, or Ar is 1,3-benzodioxolan-4 or 5-yl or 1,4-benzodioxan-5 or 6-yl; ZA is a pharmaceutically acceptable anion; with the proviso that when W is a direct link and R is optionally fused and optionally substituted heteroaryl, said heteroaryl is linked by a ring carbon atom to the carbonyl group. The compounds are tachykinin antagonists.

  本发明提供了一种具有化学式(I)的化合物，其中R为苯基、C3-C7环烷基或杂环芳基，每种基团均可选择性地与苯基或C3-C7环烷基融合，并可选择性地被从1到3个取代基取代，每个取代基独立地选自C1-C4烷基、氟代(C1-C4)烷基、C1-C4烷氧基、氟代(C1-C4)烷氧基、苯氧基、C2-C4烷酰基、卤素、C1-C4烷氧羰基、C3-C7环烷基、—S(O)m(C1-C4烷基)、氰基、—NR2R3、—S(O)mNR2R3、—NR4(C1-C4烷酰基)和—CONR2R3，或者R为2,3-二氢苯并[b]呋喃基或色基；R1为H或C1-C6烷基；W为直链、亚甲基或乙烯基；X为直链C2-C4烷基；Y为苯基、萘基、苄基、吡啶基、噻吩基或C3-C7环烷基，每个基团均可选择性地被从1到3个取代基取代，每个取代基独立地选自C1-C4烷基、氟代(C1-C4)烷基、C1-C4烷氧基、氟代(C1-C4)烷氧基、卤素和氰基；Ar为苯基、萘基、苄基、噻吩基、苯并[b]噻吩基或吲哚基，每个基团均可选择性地被从1到3个取代基取代，每个取代基独立地选自C1-C4烷基、氟代(C1-C4)烷基、C1-C4烷氧基、氟代(C1-C4)烷氧基、卤素和氰基，或者Ar为1,3-苯并二氧杜嗪-4或5-基或1,4-苯并二氧杜嗪-5或6-基；ZA为药用可接受的阴离子；但要求当W为直链且R为可选择地融合和可选择地取代的杂环芳基时，所述杂环芳基通过一个环碳原子与酰基团相连。这些化合物是Tachykinin拮抗剂。
• Neurokinin antagonists for use as medicaments
  申请人：——

  公开号：US20030158170A1

  公开（公告）日：2003-08-21

  A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

  一种具有通式(I)的化合物，以及使用此类化合物治疗疾病的方法和包含此类化合物的制药组合物。